WO2001036964A2 - Dispositif de test pour des echantillons de petits volumes (1 a 100 microlitres) - Google Patents
Dispositif de test pour des echantillons de petits volumes (1 a 100 microlitres) Download PDFInfo
- Publication number
- WO2001036964A2 WO2001036964A2 PCT/FR2000/003219 FR0003219W WO0136964A2 WO 2001036964 A2 WO2001036964 A2 WO 2001036964A2 FR 0003219 W FR0003219 W FR 0003219W WO 0136964 A2 WO0136964 A2 WO 0136964A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- analysis
- test device
- volume
- less
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 90
- 238000004458 analytical method Methods 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000001727 in vivo Methods 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- 238000011161 development Methods 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical class [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005070 sampling Methods 0.000 claims description 6
- 238000012800 visualization Methods 0.000 claims description 6
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002184 metal Chemical class 0.000 claims 1
- 229910052751 metal Chemical class 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000013558 reference substance Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 238000004445 quantitative analysis Methods 0.000 abstract description 2
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 239000012491 analyte Substances 0.000 description 34
- 239000012528 membrane Substances 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 13
- 210000001138 tear Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 238000003317 immunochromatography Methods 0.000 description 9
- 238000013508 migration Methods 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000004677 Nylon Substances 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003103 bodily secretion Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
Definitions
- This invention relates to immunoassay, immunochromatography analysis, assay devices using reagents for immunoassays, and one-step methods for performing analyzes of liquid samples suspected of containing ligands.
- this invention relates to analysis devices which are suitable for unitary use, at home, in a hospital environment or in a doctor's office, and which are intended to give a rapid analytical result and requiring the minimum of skill and practicality. , and presenting the minimum of difficulties for an inexperienced user. This is to protect an original test device allowing the use of immunochromatographic methods with very small sample volumes without reducing the sensitivity of the analysis.
- This invention makes it possible to obtain results with samples whose volume is very small, of the order of ⁇ l to a few tens of ⁇ l, by using immunochromatography or lateral migration, while calibrating the volume of sample analyzed.
- the reagent attached to the support can be an antibody, an antigen or any substance member of a specific affinity couple.
- the developing reagent which has further the feature of not being attached to a support but to be composed at least partially of a reporter molecule or which resulted in an indicator reaction.
- the most commonly used markers are dyes, radioactive substances, enzymes, colloidal gold and latex beads. Many forms of solid supports on which one of the members of an affinity couple is fixed, have been described. Currently, the most common supports for R1A and ELISA are polystyrene tubes, plates or beads.
- Radioimmunological (RIA) and enzymatic (EIA) tests are known and used worldwide. More recently developed, immunochromatographic tests have taken and continue to take an increasingly important place in the field of diagnosis. These tests mainly use membranes of various natures and compositions as a solid support.
- the immunochromatographic analysis methods use an immunochromatography support through which the sample will diffuse, either laterally and we speak of migration, or transversely and we speak then of filtration.
- gold colloids and latex beads are generally used for the optical (colored) development of the result, as components of the development or coloring reagent.
- enzymes are also used, the reaction of which with a substrate directly or indirectly produces a coloration associated with an insoluble colored product.
- sandwich technique which uses two ligands of the molecule sought, one of the ligands is fixed and the other coupled with an indicator allowing the visualization of the result, by direct coloration when it is a colored substance or by the color formation after an enzymological reaction when it is an enzyme.
- a single ligand is used as well as the desired substance or its analog; the ligand is then fixed or free and coupled with the colored or enzymatic indicator, the desired substance or its analog being inversely fixed or coupled.
- Immunochromatography has been the subject of numerous patent applications including EP 0 306 772 and EP 0 262 323 from Abbott (registered trademark), EP 0 286 371 and EP 0 183 442 from Syntex (registered trademark), EP 0 276 152 of Synbiotics Corporation (registered trademark), EP 0 296 724 of Quidel (registered trademark) and WO 88/00322 of Uniiever (registered trademark).
- Hochstrasser discloses a test strip device which can be immersed in a biological fluid for the semi-quantification of an analyte in the fluid. Also in the field of strip assay, are the U.S. patents 3,802,842, 3,915,639 and 4,689,309.
- a membrane In migration type analyzes, a membrane is soaked with the reagents required to perform the analysis. The labeled analyte is captured in a detection zone included in the membrane and where the result of the analysis is read. See, for example, Tom et al., US Patent 4,366,241, and Zuk, EP-A 0 143 574.
- the use of reagent-soaked test strips for specific catch analyzes, such as immunoassays has been proposed in patents EP 0225054, EP 0183442, EP 0186799, and GB 1589234. In such procedures, a sample is applied to part of the test strip and impregnates the strip, usually using an elution solution such as water.
- the sample progresses through a detection zone in the strip, where a capture reagent specific to the analyte suspected of being in the sample is immobilized.
- the analyte present in the sample can therefore be captured in the detection zone.
- the way in which the analyte is captured can be determined using labeled reagents which can also be incorporated into the strip or applied to it later.
- test strip chromatographic device comprising an absorbent strip having a terminal portion to come into contact with the sample.
- An analysis region is remote from the terminal part and contains an immobilized antibody deposit specific for the analyte.
- the strip also includes an unbound marker capture area including an immobilized analog of the analyte.
- an analysis solution is prepared by mixing the patient's sample with a first member of a pair of • specific igdiids, for example, a specific anti-pseudo-pseudo-conjugate for the analyte.
- immunochromatographic dipstick containing immunoreactive conjugate particuiaire is described in the patent EP 284 232 Rosenstein Becton Dickinson (indicates filed).
- the analysis device is a strip on which an immunological ligand is fixed.
- the bandeieue is immersed in or otherwise contacted with the sample, then successively contacting one or more difféientes solutions which may contain an anti - ma ⁇ qué ligand, a substrate of enzymes (for enzyme labels) and / or solutions wash to remove any uncaught marker.
- a filtration step can also be carried out to facilitate complete washing (see, for example, US Pat. No. 4,623,461).
- Other researchers have suggested using a second analysis control to verify the results. See, for example, US Patent 4,200,690: method given for the analysis of faecal samples, using two washes and incubation steps.
- Immunochromatographic methods are mainly used in unit tests allowing rapid analysis of a single sample. These tests exhibit the result of the analysis in the form of a spot or a line visible or invisible depending on the result after a time generally less than 20 minutes. The validity of the result is generally ensured by an internal operating control.
- results of the analysis and the result of the control operation are in the form of lines, dots and colorful characters, eg color red for tests using colloidal gold.
- these tests use the direct capture of the development reagent (complex composed of an affine substance and a colored indicator or an enzyme) for controlling the functioning of the test.
- the signal is generally intended to have a maximum intensity, and therefore optimal visibility.
- the sample is then brought into contact, pure or diluted, with the test device by the filter or the wick.
- small volumes are difficult to handle, and their manipulation leads to a loss of their volume and a risk of contamination of the sample but especially of the manipulator.
- the taking of the sample can prove to be delicate, either by the place of taking which can be a delicate tissue or for example a sensitive mucosa, or by its very small volume. It is in these two cases: delicate sampling and low volume, preferable to carry out an in vivo analysis, that is to say to put the test device directly in contact with the tissue which one wants to analyze, which allows '' avoid any sample collection and manipulation.
- the present invention is an original test device which makes it possible to detect one or more analytes in very small volumes, of the order of a millionth of a liter ( ⁇ l), with a sensitivity equal to or close to that obtained for usual volumes. It can also allow direct sampling to be carried out in vivo. The analysis is then made in vivo.
- the invention also describes a device and a method for calibrating the sample volume used for the analysis, and indicating that the minimum necessary volume of sample has indeed been taken by the device.
- the immunochromatographic methods to which the present invention applies are characterized by the fact that their object is the detection and possibly the determination of an analyte in a sample. They may or may not include at least one internal operation control or operation indicator, which can be used in the present invention for the calibration of the sample volume.
- this original test device is to allow the detection of analyte (s) in low-volume samples with immunochromatography tests by membrane migration, using a colored visual indicator, which may be colloidal gold, latex beads, any particulate substance or not, or the product of one or more enzymological reactions, and giving a coloration for the indication of the result.
- a colored visual indicator which may be colloidal gold, latex beads, any particulate substance or not, or the product of one or more enzymological reactions, and giving a coloration for the indication of the result.
- test device using a precise methodology and the aforementioned techniques, allows firstly the direct contact of samples of small volumes with an immuno-chromatographic analysis device, secondly to reduce the volume of sample necessary for thirdly, to indicate to the performer of these tests that this minimum volume necessary for the analysis has indeed been taken by said tests.
- low volumes is meant volumes between 0 and 100 ⁇ l.
- test device of the present invention calls upon the concepts used in immunoassays in heterogeneous phase, and on the principles of fluid mechanics, material physics, chromatography, and immunofixation. In particular, it uses the concept of dead volume of materials.
- the dead volume of analysis will be defined as the minimum sample volume necessary for obtaining valid analysis results.
- the object of the present invention is to reduce the dead analysis volume, to take a sample volume equal to or greater than this and less than or equal to 100 ⁇ l and to bring it into contact with the analysis device . , its use for the desired analysis, as well as the calibration of the sample volume used in any analysis in order to obtain good reproducibility of the results.
- This test device is in particular characterized by the fact that its dead volume can be less than 100 ⁇ l and even 10 ⁇ l. Lateral immunochromatography tests are made up of 4 distinct parts:
- a wick accompanied optionally a filter allows contacting the strip with the sample while the filter.
- the wicks and filters are generally composed of membranes, the material of which may be cellulosic, or nylon, or one or several polymers or fibers. The purpose of the wick is to bring the sample into contact with the analysis device, the filter has the function of preventing the passage of materials or particles which may interfere with the analysis.
- a first reactive zone composed of a membrane intended to receive a sample of fluid to be tested and containing half a pair of specific affinity of the ligand sought and coupled to a reagent allowing the demonstration of the presence of the ligand sought.
- This membrane is composed of a material which can act as a container (for example cellulose or cellulose derivatives, nylon, fibrous or microporous polymers of high density polyester type for example, fibers of plant, animal, mineral or synthetic origin, under in the form of powder, tablets or multiple layers) and having, with or without treatment, properties of low adsorption of biological molecules.
- a second reactive zone composed of an activated membrane having properties of selective adsorption of molecules (for example by ionic interactions, by hydrophobic interactions, by affinity, by immunoaffinity) and migration properties and capillarity allowing the sample to be tested to move and thus to drive the element to be assayed through the reactive zones.
- This membrane may or may not be composed of two distinct and contiguous parts having or not the properties set out above.
- This membrane can be composed of one or more materials having the properties set out above (for example cellulose or cellulose derivatives, nylon, fibrous or microporous polymers of high density polyester type for example, fibers of plant, animal or mineral origin. or synthetic, in the form of powder, tablets or multiple layers).
- a test area where the results for the detection of one analyte to be read, an operation control zone, and in the context of the present invention, a volumetric control.
- the purpose of the operation indicator is to indicate that the analysis has been carried out correctly and that the analysis device was functional when it was used. It is generally constituted by a ligand of the development reagent, this ligand being fixed on the support.
- volumetric control signal indicates that the volume of sample required and sufficient for the analysis has been taken by the device.
- This volumetric indicator may or may not be the operation control, then used for these two functions.
- a last part, called absorbent whose role is to cause and / or promote the flow through the two previous parts.
- This element can be composed of a material having hygroscopic properties (for example cellulose wadding or cellulose derivatives, nylon, fibrous or microporous polymers of high density polyester type for example, fibers of vegetable, animal, mineral or synthetic origin, in the form of powder, tablets or multiple layers).
- the first sector includes the test showing the result of the analysis.
- the second includes the control indicating that the test has been carried out in good conditions: operation indicator. In the context of the present invention, it can also include the volumetric indicator.
- the first three parts are generally made up of membranes of various kinds (cellulose, nitrocellulose, nylon, glass fibers, etc.).
- each of these first three parts is subject to modifications whose aim is to reduce their dead volume with the constraints of retaining the specificity and sensitivity of the desired results.
- the membranes having the thinnest thickness therefore having a lower dead volume.
- the reading of the results is therefore done on the surface of the reaction support. So that the results are visible to the maximum, it is therefore necessary to privilege the surface to the thickness.
- First part filter and / or wick.
- a filter When a filter is required, it can also act as a wick to remove additional dead volume.
- the length of the filter or wick will be set at the minimum necessary for the sampling of the sample, less than 5 millimeters when the analysis is done in vitro, and the length necessary for the sampling for an in vivo analysis, generally less than 10 millimeters.
- the width of the filter or the wick can possibly intervene for its filtration function when it is vital and made a significant contribution, but this is generally not the case.
- the reduction in its width will eventually only result in a minimal slowing down of the analysis.
- the width of the filter or wick can then be reduced to a minimum.
- the wick must be composed of a material devoid of any toxicity and non-allergenic, of a width or diameter less than 5 millimeters, of a length less than 10 millimeters.
- the wick of an in vivo test device must therefore have an area of less than 50 mm 2 , priority must be given to its length which must be sufficient for good contacting in vivo.
- Second part the reservoir or first reactive zone.
- the part called reservoir only has the function of bringing the sample into contact with a sufficient quantity of development reagent, for a given width of the second reactive zone. It is therefore generally sufficient to maintain the proportionality of the width of the first three zones to preserve the characteristics of the analysis.
- the filter or the wick also acts as a reservoir, the development reagent being deposited downstream, according to the direction of diffusion, of the part brought into contact with the sample. This ensures that the development reagent does not come into contact with the patient during an in vivo analysis. For additional safety, it can also be checked beforehand that the development reagent does not present any toxicity in vivo.
- Third part second reactive zone or support of the reaction. This zone is that of the reading of the result (s), the functional check and the volumetric check.
- the third part includes the test and possibly the operation indicator. These two indicators generally call for affinity reactions, between the analyte sought (A) and a ligand fixed (La) for the test, and between the development reagent and a ligand fixed for the control of functioning.
- the effective concentrations are dependent on the rate of diffusion in the support.
- the membrane used for the third part, supporting the reaction must have a lateral diffusion speed which is just sufficient for carrying out the analysis in the fixed time, but as slow as possible in order to allow the maximum reduction in the length of this part. , without loss of sensitivity.
- the other factor to take into account for the reduction of the length of this part is the variation of the migration speed of the diffusion front of the sample as a function of the distance traveled by it.
- this distance must allow the formation as complete as possible of the analyte - reagent reagent complexes.
- the third part is in fact the most delicate part to modify, due on the one hand to the fact that it contains the result reading and operation control zones, on the other hand that it must also contain the volumetric control of the analyzed sample.
- the methodology for defining its characteristics, in particular its length and the location of the different result areas, is therefore the subject of a particular chapter which will be found below.
- the width of these different parts must be less than 2 mm, a width between 1 and 2 mm being sufficient for easy reading of the results.
- the width of these different parts must be less than 5 millimeters.
- the methodology for determining the exact distance between the start of this part and the location of the attached ligands is as follows: Samples containing the limit concentration of analyte which it is desired to be able to detect are analyzed with devices in which this distance has been varied, the sample volume being in excess. The minimum distance for obtaining an analyte detection signal is thus determined. ! 1 there are then two options concerning the sample volume and its calibration or control:
- the volumetric control is placed a few millimeters downstream of the test area.
- the width of the first three parts is then reduced so as to obtain a positive signal in the test zone with the minimum volume of sample for which the analysis device is intended, this sample containing the limit concentration of analyte which is wants power detected.
- This width is less than 5 millimeters for sample volumes less than 100 ⁇ l and less than 2 millimeters for sample volumes less than 20 ⁇ l.
- the distance separating the test zone from the volumetric indicator is then increased until the latter gives a signal with the fixed sample volume, without giving it with a volume just below. It should moreover be specified that an accuracy greater than 90% can commonly be obtained when the sample volume thus checked.
- the length of the analytical part must be less than 70 millimeters for samples of volume less than 100 ⁇ l, its width less than 5 millimeters and its surface less than 450 mm 2 .
- the analytical part defined as the part including the zone d analysis and the volumetric control zone, should have a maximum surface of 4.5 mm 2 per ⁇ l of sample, ie 45 mm 2 for 10 ⁇ l, or even 450 mm 2 for 100 ⁇ l.
- the minimum sample volume for the test once the different lengths and widths of the first three parts have been reduced to the minimum necessary, the length of the analytical part reduced to less than 70 millimeters, its width to less than 5 millimeters and its surface less than 450 mm 2 for sample volumes less than 100 ⁇ l, various analyzes are carried out with sample volumes variables, containing the limit analyte concentration that we want to be able to detect. The minimum volume for obtaining the signal is then determined.
- absorbent is then placed as close as possible to the strip of the operating indicator, this in order to reduce the duration of the analysis and allow obtaining the results as quickly as possible.
- the volumetric indicator is also the indicator that the test is working properly.
- the latter is generally constituted by the capture of the development reagent by a ligand fixed on the membrane.
- the volumetric control can in fact be constituted by the capture of an analyte present in the sample, the so-called reference analyte.
- a revelation reagent identical or different from that allowing the visualization of the results of the analysis, will allow its visualization.
- This control which does not directly depend on the sample volume, is useful in the case where it is desired to control the sample volume by the detection of another analyte than that for which the analysis is intended, an analyte present constantly in the samples. It can also be useful if it is necessary to reference the result of the analysis not in relation to a sample volume, but in relation to a determined quantity of a reference analyte. Mention may be made, for example, of serum albumin or that present in tears, various types of immunoglobulins or any other analyte to which the results concerning the analyte sought are generally referred. It can also be a precursor, metabolite or a competitive compound for the metabolism of the analyte sought.
- This second version has the particularity that the volumetric control calibrates not the sample volume but a determined quantity of an analyte present in the sample.
- This version can be useful when the aim of the analysis is not to simply determine the presence or the level of an analyte, but an abnormal ratio of the concentration of an analyte compared to a so-called reference analyte.
- reference analyte include for example, but not limited nor exhaustive, albumin, various proteins in the blood or other tissues, the different classes of immunoglobulins. For example, it may be to compare or measure the ratio of specific antibody levels to an antigen with the rate of antibodies specific for another antigen.
- volumetric control it is also possible to use a volumetric control to determine a flow rate of fluid or sample in vivo, as well as its viscosity by temporal analysis.
- This example relates to a rapid lateral immunochromatography test for the detection of total IgE in human tears, according to the sandwich method.
- test device In order to collect the sample as simply as possible, to perform an analysis with a small volume of tears in a reasonable time, while avoiding stimulating the tear flow with irritants, a test device was developed according to the present invention.
- the device comprises a wick filter also serving as a reservoir for the development reagent, a membrane on which the IgE detection zone is situated and an operating indicator which also serves for the calibration of the sample volume, operating by capturing the reagent. of revelation.
- the test device has a width of
- the analysis device was adjusted to operate with a sample volume of 10 ⁇ l. Its analytical part therefore has an area of less than 45 mm 2 .
- the practitioner does not have to collect tears to perform, he just has to set up the test, at the corner of the eye in the conjunctival sac.
- the size and composition of the device were thus optimized for a minimum volume of tears.
- the contact time of the test device with the eye is less than 3 minutes.
- the volume of tears collected is calibrated using the operating indicator, which therefore also acts as a volumetric indicator. A signal appears when a sufficient volume
- volumetric indicator gives a visible signal
- 10 ⁇ l of tears were collected by the device. This is then removed from the eye and brought into contact with a solution allowing the sample taken to diffuse throughout the analysis device.
- a solution allowing the sample taken to diffuse throughout the analysis device.
- it is 30 ⁇ l of demineralized water, but other solutions can be used, their composition then being defined for optimal functioning of the analysis.
- This device was thus able to be validated on different samples, with the obtaining of a satisfactory agreement between the interpretation of the results (reading) and the values of the IgE levels determined by a recognized quantitative method.
- the same test device also makes it possible to detect total IgE in the discharge from the nose, in the case of suspected allergic rhinitis.
- the test device of the present invention is applicable to any analysis using an affine or non-affine reaction, comprising an internal operating control, and characterized by the presence of a reagent fixed on a support, which can be, without limitation, a membrane. , and the use of a development reagent.
- the development reagent may comprise particulate components giving a coloration or reactive molecules, for example and without limitation, enzymes, the reaction of which makes it possible to obtain a coloration, or an absence of coloration, indicative of the nature of the result .
- This device can be used for any detection of an element liable to intervene in an affinity reaction with a counter-element.
- Element is understood to mean, within the framework of this presentation, any substance, composition, particle capable of intervening in a ligand-refining system, in particular in an affine reaction with a “counter-element”.
- the generality given to the word “element” therefore also extends to the expression “counter-element”.
- “element” and “counter-element” can consist of a mutually complementary, affine antigen and antibody, or vice versa.
- the element sought by this test device may be of a biological nature, an antibody or an antigen, of a chemical or biochemical nature.
- This test device and this method is applicable to the detection of any biological marker of one or more infectious pathologies, for example and in a non-exhaustive manner serology tests, and antigen detection tests.
- This test device and this method are also applicable when the element sought is a single type of antibody or several types, classes or subclasses.
- a specific example to which the claims of this patent is not limited in any way is the serology HIV or Chlamydia, and for which this device and this method make it possible to determine or evaluate the level of antibodies directed against a specific antigen, in the serum or other samples, by calibrating it against the level of antibodies against another antigen.
- This test device and this method are also applicable when the element sought is one or more antigens specific for one or more pathologies.
- This test device and this method are also applicable in the context of therapeutic monitoring.
- This test device and this method are also applicable for any type of sample, whether human, animal or plant tissue, whether solid or liquid. It is applicable with any type of sample, for example and without limitation: bodily secretions, mucus, sweat, tears, lacrimal and nasal fluids, saliva, mood, pus.
- this test device can allow the characterization of microorganisms in the liquids of abscesses, panaris, and oozing from wounds.
- This test device is also applicable to any in vitro analysis on samples of small volume, for example taken from children and infants. It can also make it possible to carry out analyzes on meat samples, whether for the purpose of researching microorganisms, or of putrefaction marker or any other biological, biochemical or chemical marker.
- the test device therefore allows the detection of any analyte, for example for diagnosis in human health, in samples of small volume which can also be difficult to take.
- the present invention is applicable to research in biology and in the field of medical diagnosis, as well as in all fields of diagnostic and analytical sciences, such as veterinary, agricultural, agro-food, food and expertise sciences. , where it is necessary to detect an element, compound or substance, or to determine its rate. It is also applicable in industry, and to any qualitative detection process used industrially.
- This test device can be used either with a visual reading, carried out by a human operator, or with a reading device coupled or not with a data processing device.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU18691/01A AU1869101A (en) | 1999-11-19 | 2000-11-20 | Device for testing in vivo samples between 1 to 100 mul |
JP2001538801A JP4470354B2 (ja) | 1999-11-19 | 2000-11-20 | 1〜100ulの試料のためのインビボ検査装置 |
EP00981444A EP1305629A2 (fr) | 1999-11-19 | 2000-11-20 | Dispositif de test pour des echantillons de petits volumes (1 a 100 microlitres) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9914688A FR2801386A1 (fr) | 1999-11-19 | 1999-11-19 | Dispositif de test pour l'analyse de faibles volumes d'echantillons par des methodes immunochromatographiques |
FR99/14688 | 1999-11-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001036964A2 true WO2001036964A2 (fr) | 2001-05-25 |
WO2001036964A3 WO2001036964A3 (fr) | 2001-11-22 |
WO2001036964B1 WO2001036964B1 (fr) | 2002-07-25 |
Family
ID=9552408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/003219 WO2001036964A2 (fr) | 1999-11-19 | 2000-11-20 | Dispositif de test pour des echantillons de petits volumes (1 a 100 microlitres) |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1305629A2 (fr) |
JP (1) | JP4470354B2 (fr) |
KR (1) | KR20030031878A (fr) |
AU (1) | AU1869101A (fr) |
FR (1) | FR2801386A1 (fr) |
WO (1) | WO2001036964A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004057499B4 (de) * | 2003-12-19 | 2010-07-29 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | Ein Verfahren und eine Vorrichtung zum Erzeugen von unverfärbtem, weissem Licht unter Verwendung von gebrochen weissen Lichtemittierungsdioden |
EP2418485A1 (fr) * | 2009-04-09 | 2012-02-15 | Hitachi Chemical Company, Ltd. | Détecteur et procédé de détection |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1718973B1 (fr) * | 2004-02-09 | 2009-09-09 | Rapid Pathogen Screening Inc. | Procede de diagnostic rapide de cibles dans des liquides corporels humains |
US8445293B2 (en) | 2005-02-09 | 2013-05-21 | Rapid Pathogen Screening, Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0362809A1 (fr) * | 1988-10-06 | 1990-04-11 | BOEHRINGER BIOCHEMIA ROBIN S.p.A. | Appareil et procédé pour la détection d'un analyte |
WO1994006012A1 (fr) * | 1992-09-03 | 1994-03-17 | Boehringer Mannheim Corporation | Appareil de test analytique dote de temoins negatif et positif incorpores |
WO1995027205A1 (fr) * | 1994-03-30 | 1995-10-12 | Epitope, Inc. | Dispositif et procede de dosage de la salive |
WO1995035502A1 (fr) * | 1994-06-17 | 1995-12-28 | Trinity Biotech Inc. | Dispositif de detection de substances polyvalentes |
US5648274A (en) * | 1991-05-29 | 1997-07-15 | Smithkline Diagnostics, Inc. | Competitive immunoassay device |
EP0806666A2 (fr) * | 1996-05-09 | 1997-11-12 | Syntron Bioresearch, Inc. | Procédé et appareil pour essais de sang complet en un seul temps |
-
1999
- 1999-11-19 FR FR9914688A patent/FR2801386A1/fr not_active Withdrawn
-
2000
- 2000-11-20 AU AU18691/01A patent/AU1869101A/en not_active Abandoned
- 2000-11-20 JP JP2001538801A patent/JP4470354B2/ja not_active Expired - Lifetime
- 2000-11-20 EP EP00981444A patent/EP1305629A2/fr not_active Withdrawn
- 2000-11-20 KR KR1020027006706A patent/KR20030031878A/ko not_active Application Discontinuation
- 2000-11-20 WO PCT/FR2000/003219 patent/WO2001036964A2/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0362809A1 (fr) * | 1988-10-06 | 1990-04-11 | BOEHRINGER BIOCHEMIA ROBIN S.p.A. | Appareil et procédé pour la détection d'un analyte |
US5648274A (en) * | 1991-05-29 | 1997-07-15 | Smithkline Diagnostics, Inc. | Competitive immunoassay device |
WO1994006012A1 (fr) * | 1992-09-03 | 1994-03-17 | Boehringer Mannheim Corporation | Appareil de test analytique dote de temoins negatif et positif incorpores |
WO1995027205A1 (fr) * | 1994-03-30 | 1995-10-12 | Epitope, Inc. | Dispositif et procede de dosage de la salive |
WO1995035502A1 (fr) * | 1994-06-17 | 1995-12-28 | Trinity Biotech Inc. | Dispositif de detection de substances polyvalentes |
EP0806666A2 (fr) * | 1996-05-09 | 1997-11-12 | Syntron Bioresearch, Inc. | Procédé et appareil pour essais de sang complet en un seul temps |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004057499B4 (de) * | 2003-12-19 | 2010-07-29 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | Ein Verfahren und eine Vorrichtung zum Erzeugen von unverfärbtem, weissem Licht unter Verwendung von gebrochen weissen Lichtemittierungsdioden |
EP2418485A1 (fr) * | 2009-04-09 | 2012-02-15 | Hitachi Chemical Company, Ltd. | Détecteur et procédé de détection |
EP2418485A4 (fr) * | 2009-04-09 | 2013-04-10 | Hitachi Chemical Co Ltd | Détecteur et procédé de détection |
US9046518B2 (en) | 2009-04-09 | 2015-06-02 | Hitachi Chemical Company, Ltd. | Detector and detection method |
Also Published As
Publication number | Publication date |
---|---|
EP1305629A2 (fr) | 2003-05-02 |
JP2005529305A (ja) | 2005-09-29 |
AU1869101A (en) | 2001-05-30 |
FR2801386A1 (fr) | 2001-05-25 |
KR20030031878A (ko) | 2003-04-23 |
JP4470354B2 (ja) | 2010-06-02 |
WO2001036964B1 (fr) | 2002-07-25 |
WO2001036964A3 (fr) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kroll et al. | Interference with clinical laboratory analyses | |
US9939434B2 (en) | Multiplanar lateral flow assay with sample compressor | |
AU2010325893B2 (en) | Multiplanar lateral flow assay with sample compressor | |
JPH11503025A (ja) | 現在のグルコースレベルおよび中期間または長期間の血糖症制御のための組み合わせアッセイ | |
FR2630827A1 (fr) | Dispositif et procede pour la determination qualitative et quantitative rapide de la presence d'un ligand reactif dans un fluide | |
US7931788B1 (en) | Method and apparatus for the detection of pathogens, parasites, and toxins | |
Puchades et al. | Recent developments in flow injection immunoanalysis | |
WO1989003039A1 (fr) | Dispositif de detection immunoenzymatique | |
Allameh et al. | A distance-based microfluidic paper-based biosensor for glucose measurements in tear range | |
EP1879028A1 (fr) | Utilisation d'albumine, P-aminophényl N-acétyl ß-D glucosaminide bovine en tant que voie de contrôle pour dispositif de dosage immunologique | |
JP3757171B2 (ja) | 微生物抗原の抽出方法 | |
KR20190058357A (ko) | 고농도 검체 내 표적물질 정량화가 가능한 광범위 체외 진단 키트 | |
JPH02504188A (ja) | 複数分析の免疫検定用毛細管装置 | |
WO2015064701A1 (fr) | Kit de mesure et procédé de mesure de glycoalbumine | |
JP2007139658A (ja) | アレルゲン検出方法及びアレルゲン検出装置 | |
WO2001036964A2 (fr) | Dispositif de test pour des echantillons de petits volumes (1 a 100 microlitres) | |
AU2002225017B2 (en) | Test device | |
JP2009192222A (ja) | 免疫学的測定方法 | |
FR2788856A1 (fr) | Dispositif de test et procede pour la quantification de resultats obtenus par des methodes immunochromatographiques | |
AU2002225017A1 (en) | Test device | |
WO1996010179A1 (fr) | Diagnostic direct d'haptenes | |
Benninga et al. | Sepsis ‘PSP test’on the abioSCOPE Device: 5 minutes to save lives | |
JP3895307B2 (ja) | 対象物質の定量方法及び定量チップ | |
JP6939106B2 (ja) | イムノクロマト試験片およびキットおよび測定方法 | |
GB2571763A (en) | Enzyme-amplified lateral flow device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000981444 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027006706 Country of ref document: KR |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 538801 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027006706 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000981444 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000981444 Country of ref document: EP |